Analytical Data
-
Gene name
IFNa3
- Application
-
Alternative Names
IFNa3;Interferon a3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14879
-
Expression Region
1-490aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMGSMSEVTKNSLEKILPQLKCHFTWNLFKE DSVSRDLEDRVCNQIEFLNTEFKATMYNLLAYIKHLDGNNEAALECLRQA EELIQQEHADQAEIRSLVTWGNYAWVYYHLGRLSDAQIYVDKVKQTCKKF SNPYSIEYSELDCEEGWTQLKCGRNERAKVCFEKALEEKPNNPEFSSGLA IAMYHLDNHPEKQFSTDVLKQAIELSPDNQYVKVLLGLKLQKMNKEAEGE QFVEEALEKSPCQTDVLRSAAKFYRRKGDLDKAIELFQRVLESTPNNGYL YHQIGCCYKAKVRQMQNTGESEASGNKEMIEALKQYAMDYSNKALEKGLN PLNAYSDLAEFLETECYQTPFNKEVPDAEKQQSHQRYCNLQKYNGKSEDT AVQHGLEGLSISKKSTDKEEIKDQPQNVSENLLPQNAPNYWYLQGLIHKQ NGDLLQAAKCYEKELGRLLRDAPSGIGSIFLSASELEDGSEEMGQGAVSS SPRELLSNSEQLN
-
Molecular Weight
58 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNa3 (Interferon alpha 3) is a member of the interferon-alpha family, which plays a critical role in the immune response to viral infections. Research into IFNa3 has gained momentum due to its potential therapeutic applications, particularly in the treatment of viral diseases such as hepatitis C and certain types of cancers. As a cytokine, IFNa3 is known for its antiviral, antiproliferative, and immunomodulatory effects, which make it a subject of interest in both basic and clinical research. Studies have shown that recombinant IFNa3 can enhance the antiviral state of cells, stimulate the immune system, and inhibit tumor cell proliferation. Furthermore, advancements in recombinant DNA technology have enabled the production of IFNa3 in quantities sufficient for therapeutic use. Understanding the molecular mechanisms underlying the action of IFNa3 can facilitate the development of more effective antiviral therapies and strategies to enhance the immune response against malignancies. As research continues, evaluating the efficacy, safety, and potential side effects of IFNa3 in various clinical settings remains a critical focus, guiding its integration into modern therapeutic protocols.











